Ready or not, legal marijuana is taking North America by storm. Even though the U.S. federal government has held firm on marijuana as a Schedule I drug (i.e., entirely illegal, prone to abuse, and not recognized as having any medical benefits), we’ve nevertheless witnessed 32 states legalize medical weed in some capacity. To our south, Mexico legalized medical pot in the summer of 2017 and is now strongly considering legalizing adult-use weed. And to our north, on Oct. 17, Canada became the first industrialized country in the world to give the green light to recreational cannabis.
According to investment firm Cowen Group, which has been one of the most optimistic Wall Street firms on the outlook for global cannabis, the industry could hit $75 billion in annual sales by 2030. This pie-in-the-sky sales figure is a big reason behind the lofty valuations of most marijuana stocks.
CBD is where the big money is
Cannabidiol, like THC, comes from the cannabis plant (although CBD can also be found in abundance via hemp). However, CBD doesn’t get a user high. Rather, it’s best known for its perceived medical benefits.
For example, GW Pharmaceuticals (NASDAQ:GWPH) earlier this year became the first drug developer to have the U.S. Food and Drug Administration approve a cannabis-derived therapy. Epidiolex, as it’s known, is an oral CBD-based medicine that’s designed to treat two rare forms of childhood-onset epilepsy. In clinical trials, GW Pharmaceuticals’ lead drug wound up significantly reducing seizure frequency from baseline relative to a placebo. Eventual sales of GW Pharmaceuticals’ top drug may top $500 million annually, but that will, of course, depend on insurer coverage and the willingness of physicians to prescribe Epidiolex.
According to the Brightfield Group, a cannabis analytics firm, the CBD market is on track to generate $591 million in sales in 2018. However, by 2022, hemp-CBD sales are projected to reach… drumroll… $22 billion. For you math-phobes out there, this represents a compound annual growth rate of 147% over the next four years.
What’s more, CBD-rich products tend to be a considerably higher-margin item than traditional dried cannabis flower. Though focused on a smaller group of consumers than dried flower, CBD products have little in the way of pricing pressures or oversupply concerns.
These pot stocks are focusing on CBD products
In other words, marijuana stocks that incorporate CBD products into their portfolios have a much better opportunity to improve their operating margins over the long run, as well as avoid any pricing pressures caused by an oversupply of dried flower.
While it could be many quarters before we see pot stocks generating operating profits, companies that place added focus on CBD-rich products should be in much better shape than their peers with regard to operating margins.
This Marijuana Stock Could be Like Buying Amazon for $3.19
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming.
Cannabis legalization is sweeping over North America – 10 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.
And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.
Because a game-changing deal just went down between the Ontario government and this powerhouse company…and you need to hear this story today if you have even considered investing in pot stocks.